Coronary Artery DiseaseBCIS-1NCT00910481
Balloon Pump Assisted Coronary Intervention Study
A study testing Intra-Aortic Balloon Pump in people with Coronary Artery Disease and Left Ventricular Dysfunction, run by British Cardiovascular Intervention Society at 1 site in United Kingdom.
Trial summary
This study will test the hypothesis that elective use of the Intra-Aortic Balloon Pump (IABP) in patients undergoing high-risk Percutaneous Coronary Intervention (PCI) will reduce the rate of in-hospital major adverse cardiac and cerebrovascular events compared to patients who are managed without planned insertion of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease, Left Ventricular Dysfunction
- What is being tested?
- Intra-Aortic Balloon Pump
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 301 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Dec 2005to Dec 2012
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- impaired left ventricular function (Ejection Fraction < 30%)
- large area of myocardium at risk (BCIS-1 Myocardial Jeopardy Score ≥ 8/12)
Who cannot join
- cardiogenic shock
- acute STEMI within previous 48 hours
- complications of recent AMI (including ventricular septal defect, severe mitral regurgitation, intractable ventricular arrhythmias)
- contraindications to IABP use (including significant iliac or femoral arterial disease and more than mild aortic regurgitation)
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
British Cardiovascular Intervention Society
London
About this study
This study will test the hypothesis that elective use of the Intra-Aortic Balloon Pump (IABP) in patients undergoing high-risk Percutaneous Coronary Intervention (PCI) will reduce the rate of in-hospital major adverse cardiac and cerebrovascular events compared to patients who are managed without planned insertion of IABP.
- Being tested
- Intra-Aortic Balloon Pump
- Keywords
- Coronary Artery Disease, Percutaneous Transluminal Coronary Angioplasty, Intraaortic Balloon Pumping, Left Ventricular Dysfunction, High Risk
- Medical subject headings
- Coronary Artery Disease, Ventricular Dysfunction, Left
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intra-Aortic Balloon PumpDevice
Elective IABP insertion before PCI
| Study group | Role | What they receive |
|---|---|---|
| Elective IABP Insertion | Experimental | Not described Receives: Device: Intra-Aortic Balloon Pump |
| No Planned IABP Insertion | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major Adverse Cardiac and Cerebrovascular Events
(composite endpoint of death, acute myocardial infarction, further revascularization or cerebrovascular event)
Measured: Hospital discharge or 28 days following PCI, whichever occurs sooner
Secondary outcomes (7)
All-cause Mortality
Measured: 6-months following randomization
Major Procedural Complications
Measured: Duration of PCI procedure
Bleeding Complications (Major and Minor)
Measured: Hospital Discharge or 28 days following PCI (whichever occurs sooner)
Access Site Complications
Measured: Hospital Discharge or 28 days following PCI (whichever occurs sooner)
Transient Ischemic Attack
Measured: Hospital Discharge or 28 days following PCI (whichever occurs sooner)
Length of Hospital Stay
Measured: Hospital Discharge
Procedural Success
Measured: Duration of PCI procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2009 (estimated)
- Study startDec 2005
- Primary completionJan 2011
- Study completionDec 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 301 participants (actual)
Sponsor and investigators
- Lead sponsor
- British Cardiovascular Intervention Society
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Divaka Perera, British Cardiovascular Intervention Society
- Investigators
- Divaka Perera, MRCP, MD, Principal investigator, Guy's and St Thomas' Hospital NHSFT, London, UKSimon Redwood, FRCP, MD, Principal investigator, Guy's and St Thomas' Hospital NHSFT, London, UKRodney Stables, FRCP, DM, Principal investigator, Liverpool Cardiothoracic Centre, Liverpool, UKMartyn Thomas, FRCP, MD, Principal investigator, Guy's and St Thomas' Hospital NHSFT, London, UK
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00910481
- Sponsor's protocol ID
- ISRCTN40553718
- Other IDs
- ISRCTN40553718
- Acronym
- BCIS-1
- Status last verified
- Aug 2024
- First submitted
- 28 May 2009
- Last updated
- 7 Aug 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Perera D, Stables R, Clayton T, De Silva K, Lumley M, Clack L, Thomas M, Redwood S; BCIS-1 Investigators. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation. 2013 Jan 15;127(2):207-12. doi: 10.1161/CIRCULATIONAHA.112.132209. Epub 2012 Dec 6.
PubMed 23224207Perera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D, de Belder A, Redwood S; BCIS-1 Investigators. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA. 2010 Aug 25;304(8):867-74. doi: 10.1001/jama.2010.1190.
PubMed 20736470Perera D, Stables R, Booth J, Thomas M, Redwood S; BCIS-1 Investigators. The balloon pump-assisted coronary intervention study (BCIS-1): rationale and design. Am Heart J. 2009 Dec;158(6):910-916.e2. doi: 10.1016/j.ahj.2009.09.015.
PubMed 19958856
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Balloon Pump Assisted Coronary Intervention Study
- ClinicalTrials.gov ID
- NCT00910481
- Acronym / sponsor ID
- BCIS-1 / ISRCTN40553718
- Keywords
- Coronary Artery Disease, Percutaneous Transluminal Coronary Angioplasty, Intraaortic Balloon Pumping, Left Ventricular Dysfunction, High Risk
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 301 participants (actual)
- Lead sponsor
- British Cardiovascular Intervention SocietyUniversity, hospital or other
- Study start
- Dec 2005
- Primary completion
- Jan 2011 (actual)
- Study completion
- Dec 2012 (actual)
- First posted
- 29 May 2009 (estimated)
- Results
- Posted 25 Feb 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will test the hypothesis that elective use of the Intra-Aortic Balloon Pump (IABP) in patients undergoing high-risk Percutaneous Coronary Intervention (PCI) will reduce the rate of in-hospital major adverse cardiac and cerebrovascular events compared to patients who are managed without planned insertion of IABP.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Elective IABP Insertion | Experimental | Device: Intra-Aortic Balloon Pump |
| No Planned IABP Insertion | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- impaired left ventricular function (Ejection Fraction < 30%)
- large area of myocardium at risk (BCIS-1 Myocardial Jeopardy Score ≥ 8/12)
Key exclusion criteria (4 listed)
- cardiogenic shock
- acute STEMI within previous 48 hours
- complications of recent AMI (including ventricular septal defect, severe mitral regurgitation, intractable ventricular arrhythmias)
- contraindications to IABP use (including significant iliac or femoral arterial disease and more than mild aortic regurgitation)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intra-Aortic Balloon PumpElective IABP insertion before PCI | Device | Elective IABP Insertion |
Primary outcome
Major Adverse Cardiac and Cerebrovascular Events
Time frame: Hospital discharge or 28 days following PCI, whichever occurs sooner
(composite endpoint of death, acute myocardial infarction, further revascularization or cerebrovascular event)
7 secondary outcomes
All-cause Mortality
Time frame: 6-months following randomization
Major Procedural Complications
Time frame: Duration of PCI procedure
Bleeding Complications (Major and Minor)
Time frame: Hospital Discharge or 28 days following PCI (whichever occurs sooner)
Access Site Complications
Time frame: Hospital Discharge or 28 days following PCI (whichever occurs sooner)
Transient Ischemic Attack
Time frame: Hospital Discharge or 28 days following PCI (whichever occurs sooner)
Length of Hospital Stay
Time frame: Hospital Discharge
Procedural Success
Time frame: Duration of PCI procedure
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 23224207Perera D, Stables R, Clayton T, De Silva K, Lumley M, Clack L, Thomas M, Redwood S; BCIS-1 Investigators. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation. 2013 Jan 15;127(2):207-12. doi: 10.1161/CIRCULATIONAHA.112.132209. Epub 2012 Dec 6.
- Results publication: PubMed 20736470Perera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D, de Belder A, Redwood S; BCIS-1 Investigators. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA. 2010 Aug 25;304(8):867-74. doi: 10.1001/jama.2010.1190.
- Derived from this study: PubMed 19958856Perera D, Stables R, Booth J, Thomas M, Redwood S; BCIS-1 Investigators. The balloon pump-assisted coronary intervention study (BCIS-1): rationale and design. Am Heart J. 2009 Dec;158(6):910-916.e2. doi: 10.1016/j.ahj.2009.09.015.
Related trials for Coronary Artery Disease
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
Active, not recruitingPhase 3
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Coronary Artery Disease
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
Active, not recruiting
Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography
Coronary Artery Disease
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Cardiovascular Diseases, Myocardial Ischemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Divaka Perera, MRCP, MD principal investigator
Guy's and St Thomas' Hospital NHSFT, London, UK
Simon Redwood, FRCP, MD principal investigator
Guy's and St Thomas' Hospital NHSFT, London, UK
Rodney Stables, FRCP, DM principal investigator
Liverpool Cardiothoracic Centre, Liverpool, UK
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intra-Aortic Balloon Pump in people with Coronary Artery Disease and Left Ventricular Dysfunction, run by British Cardiovascular Intervention Society at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major Adverse Cardiac and Cerebrovascular Events (time frame: Hospital discharge or 28 days following PCI, whichever occurs sooner). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00910481, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2024.